Nicholas Hubbard

Nicholas Hubbard

Auto-generated profile, based on publicly available information

Nicholas Hubbard

Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2019 in Science Immunology
Verified
Journal Article
Closed access
PDF file
ASAnnelise G. Snyder
Annelise G. Snyder
NHNicholas W. Hubbard
Nicholas W. Hubbard
MMMichelle N. Messmer
Michelle N. Messmer
SKSigal B. Kofman
Sigal B. Kofman
CHCassidy E. Hagan
Cassidy E. Hagan
AOAndrew Oberst
Andrew Oberst
Although the signaling events that induce different forms of programmed cell death are well defined, the subsequent immune responses to dying cells in the context of cancer remain relatively unexplored. Necroptosis occurs downstream of the receptor-interacting protein kinases RIPK1 and RIPK3, whose activation leads to lytic cell death accompanied by de novo production of proinflammatory mediators. Here, we show that ectopic introduction of necroptotic cells to the tumor microenvironment promotes BATF3+ cDC1− and CD8+ leukocyte–dependent antitumor immunity accompanied by increased tumor antigen loading by tumor-associated antigen-presenting cells. Furthermore, we report the development of constitutively active forms of the necroptosis-inducing enzyme RIPK3 and show that delivery of a gene encoding this enzyme to tumor cells using adeno-associated viruses induces tumor cell necroptosis, which synergizes with immune checkpoint blockade to promote durable tumor clearance. These findings support a role for RIPK1/RIPK3 activation as a beneficial proximal target in the initiation of tumor immunity. Considering that successful tumor immunotherapy regimens will require the rational application of multiple treatment modalities, we propose that maximizing the immunogenicity of dying cells within the tumor microenvironment through specific activation of the necroptotic pathway represents a beneficial treatment approach that may warrant further clinical development.

20 July 2022 in Nature
Verified
Journal Article
Closed access
PDF file
NHNicholas W. Hubbard
Nicholas W. Hubbard
JAJoshua M. Ames
Joshua M. Ames
MMMegan Maurano
Megan Maurano
LCLan H. Chu
Lan H. Chu
KSKim Y. Somfleth
Kim Y. Somfleth
AOAndrew Oberst
Andrew Oberst

26 May 2016 in Blood
Verified
Journal Article
Closed access
PDF file
NHNicholas Hubbard
Nicholas Hubbard
DHDavid Hagin
David Hagin
KSKaren Sommer
Karen Sommer
YSYumei Song
Yumei Song
IKIram Khan
Iram Khan
TTTroy R. Torgerson
Troy R. Torgerson
Loss of CD40 ligand (CD40L) expression or function results in X-linked hyper-immunoglobulin (Ig)M syndrome (X-HIGM), characterized by recurrent infections due to impaired immunoglobulin class-switching and somatic hypermutation. Previous attempts using retroviral gene transfer to correct murine CD40L expression restored immune function; however, treated mice developed lymphoproliferative disease, likely due to viral-promoter–dependent constitutive CD40L expression. These observations highlight the importance of preserving endogenous gene regulation in order to safely correct this disorder. Here, we report efficient, on-target, homology-directed repair (HDR) editing of the CD40LG locus in primary human T cells using a combination of a transcription activator-like effector nuclease–induced double-strand break and a donor template delivered by recombinant adeno-associated virus. HDR-mediated insertion of a coding sequence (green fluorescent protein or CD40L) upstream of the translation start site within exon 1 allowed transgene expression to be regulated by endogenous CD40LG promoter/enhancer elements. Additionally, inclusion of the CD40LG 3′-untranslated region in the transgene preserved posttranscriptional regulation. Expression kinetics of the transgene paralleled that of endogenous CD40L in unedited T cells, both at rest and in response to T-cell stimulation. The use of this method to edit X-HIGM patient T cells restored normal expression of CD40L and CD40–murine IgG Fc fusion protein (CD40-muIg) binding, and rescued IgG class switching of naive B cells in vitro. These results demonstrate the feasibility of engineered nuclease-directed gene repair to restore endogenously regulated CD40L, and the potential for its use in T-cell therapy for X-HIGM syndrome. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points The CD40LG locus can be specifically targeted and repaired in primary human T cells by insertion of a spliced CD40LG complementary DNA. Gene editing restores regulated CD40L expression in X-HIGM T cells, reconstituting B-cell immunoglobulin class switching.

3 June 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YHYuchi Honaker
Yuchi Honaker
NHNicholas Hubbard
Nicholas Hubbard
YXYufei Xiang
Yufei Xiang
LFLogan Fisher
Logan Fisher
DHDavid Hagin
David Hagin
DRDavid J. Rawlings
David J. Rawlings
Gene editing to insert a strong promoter upstream of endogenous FOXP3 conferred T reg -like properties and functions to primary human CD4 + T cells.

25 May 2013 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
LSLena F. Schimke
Lena F. Schimke
NRNikolaus Rieber
Nikolaus Rieber
SRStacey Rylaarsdam
Stacey Rylaarsdam
OMOtavio Marques
Otavio Marques
NHNicholas Hubbard
Nicholas Hubbard
TTTroy R. Torgerson
Troy R. Torgerson

2 May 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
OHOlivier Humbert
Olivier Humbert
FCFrieda Chan
Frieda Chan
YRYogendra S. Rajawat
Yogendra S. Rajawat
TTTroy R. Torgerson
Troy R. Torgerson
CBChristopher R. Burtner
Christopher R. Burtner
HKHans-Peter Kiem
Hans-Peter Kiem
Key Points: IV delivery of FV vector using the phosphoglycerate kinase promoter outperforms EF1α-containing vector in the canine SCID-X1 model. G-CSF/AMD3100 mobilization before in vivo FV vector delivery improves kinetics and clonal diversity of lymphocyte reconstitution.